Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP29-02 vs Monotherapies and Placebo in Seasonal Allergic Rhinitis
NCT00740792Phase 3Completed
- Sponsor
- Meda
- Start
- Aug 2008
- Primary completion
- Nov 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azelastine and fluticasone propionate nasal spray in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Meda. Primary endpoint: 12 Hour Reflective Total Nasal Symptom Score at 14 days. Started Aug 2008; status: completed.
02
Drugs
azelastinefluticasone propionate nasal spray
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00740792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00740792.